137 related articles for article (PubMed ID: 28287008)
21. Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Soysal T; Eskazan AE; Ar MC
Expert Rev Hematol; 2014 Dec; 7(6):697-9. PubMed ID: 25292262
[TBL] [Abstract][Full Text] [Related]
22. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
24. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
26. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Fu J; Liu Y; Lin H; Wu B
Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
[TBL] [Abstract][Full Text] [Related]
27. Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.
Suttorp M; Metzler M; Millot F; Shimada H; Bansal D; Günes AM; Kalwak K; Sedlacek P; Baruchel A; Biondi A; Hijiya N; Schultz KR; Schrappe M
Pediatr Blood Cancer; 2018 Dec; 65(12):e27431. PubMed ID: 30160364
[TBL] [Abstract][Full Text] [Related]
28. An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
Paquin D; Sacco D; Shamshoian J
Math Biosci; 2015 Apr; 262():117-24. PubMed ID: 25659886
[TBL] [Abstract][Full Text] [Related]
29. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
31. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
32. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Giles FJ; DeAngelo DJ; Baccarani M; Deininger M; Guilhot F; Hughes T; Mauro M; Radich J; Ottmann O; Cortes J
Semin Oncol; 2008 Feb; 35(1 Suppl 1):S1-17; quiz S18-20. PubMed ID: 18346528
[TBL] [Abstract][Full Text] [Related]
33. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
34. Update on emerging treatments for chronic myeloid leukemia.
Fava C; Morotti A; Dogliotti I; Saglio G; Rege-Cambrin G
Expert Opin Emerg Drugs; 2015 Jun; 20(2):183-96. PubMed ID: 25826695
[TBL] [Abstract][Full Text] [Related]
35. Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia.
Campbell D; Blazer M; Bloudek L; Brokars J; Makenbaeva D
Am Health Drug Benefits; 2019 Nov; 12(7):333-342. PubMed ID: 32055281
[TBL] [Abstract][Full Text] [Related]
36. The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
Uyanik MS; Pamuk GE; Maden M; Merev E; Cevik G; Uyanik V; Umit EG; Demir AM; Akker M
Eur J Cancer Care (Engl); 2017 Mar; 26(2):. PubMed ID: 26594025
[TBL] [Abstract][Full Text] [Related]
37. Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.
Lyman GH; Henk HJ
JAMA Oncol; 2020 Dec; 6(12):1969-1971. PubMed ID: 33001149
[TBL] [Abstract][Full Text] [Related]
38. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
39. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
[No Abstract] [Full Text] [Related]
40. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Ohm L; Lundqvist A; Dickman P; Höglund M; Persson U; Stenke L; Carlsson KS; Björkholm M
Leuk Lymphoma; 2015 May; 56(5):1385-91. PubMed ID: 25139694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
